In January 2017, Novo Nordisk pharmaceutical company received European Commission (EMA) approval to market the new fast-acting insulin brand Fiasp in 28 European Union countries, as well as Norway and Iceland. On March 27, 2017, the drug began to enter the Canadian market.
Prandial, that is, introduced to compensate for carbohydrates from food, “accelerated” insulin Fiasp is a modified, well-known to everyone, insulin Aspart (Novorapid). Two components have been added to the innovative formulation:
On Insulin.Store, you can find the following variations of the medication:
To buy these or any other insulin products from our company Insulin.Store, you will need to attach a valid prescription for the drug from the doctor. Without the prescription, our specialists will have to decline your order.
Insulin Aspart that comprises the base for Fiasp insulin is a fast-acting human analog insulin. In the molecular structure of this insulin, the amino acid proline in position B28 is replaced by aspartic acid, which reduces the tendency of molecules to form hexamers, which is observed in ordinary insulin solutions.
The hypoglycemic effect is associated with an increase in intracellular transport and an increase in glucose uptake by tissues, stimulation of lipogenesis, glycogenogenesis, and a decrease in the rate of glucose production by the liver.
The goal of Fiasp insulin was to achieve faster onset of action and improved postprandial glycemic control.
The efficacy and safety profile of Fiasp was studied in a clinical trial program consisting of four studies covering more than 2,100 people with type 1 and type 2 diabetes. The results of three studies carried out in patients with type 1 diabetes mellitus showed that the effect of insulin begins to unfold 5 minutes earlier and reaches a peak 11 minutes faster when using insulin Fiasp compared to Novorapid. The duration of action of the new insulin was shorter, and the residual glucose-lowering effect was 10% less pronounced than that of Novorapid insulin.
Basically, these two remedies are based on insulin Aspart for glycemic control in patients with diabetes mellitus. The difference lies in the fact that Fiasp is a more innovative and advanced version of Novorapid strengthened by adding such components as Vitamin B3 (niacinamide) that helps to increase the rate of insulin absorption and amino acid L-Arginine that is added for the stability of the medication preparation.
This new formula allowed achieving better effectiveness and faster onset of action of Fiasp compared to Novorapid.
Being based on insulin Aspart, both remedies show excellent efficiency in helping to control blood glucose in patients with diabetes mellitus. Fiasp also includes vitamin B3 and amino acid L-Arginine in its composition that helps the drug act faster compared to Novorapid. However, there may be individual indications for taking Fiasp or Novorapid that depend on the blood glucose level of the patient, diet, lifestyle, and so on. Only a health care provider can prescribe a drug and determine the dose. Do not switch to another medication, change diet, or lifestyle without informing your doctor. It can become health- and life-threatening.
Side effects associated with the effect on carbohydrate metabolism: hypoglycemia (increased sweating, pallor of the skin, nervousness or tremor, anxiety, unusual fatigue or weakness, disorientation, impaired concentration, dizziness, severe hunger, temporary visual impairment, headache, nausea, tachycardia). Severe hypoglycemia can lead to loss of consciousness and/or seizures, temporary or permanent disruption of the brain, and death.
Allergic reactions: possible – urticaria, skin rash; rarely – anaphylactic reactions. Generalized allergic reactions may include skin rash, itching of the skin, increased sweating, gastrointestinal disorders, angioedema, difficulty breathing, tachycardia, and decreased blood pressure.
Injection site reactions: allergic reactions (redness, swelling, itching of the skin at the injection site), usually temporary and disappearing as treatment continues; lipodystrophy is possible.
You need a prescription to buy any insulin or insulin-like medication, including Fiasp. All officially registered companies and pharmacies must ask the patients to provide their medical prescriptions for the drugs from their health care providers before the purchase. Be careful when buying Fiasp from new and not verified companies. If they do not ask for a prescription, this is the first sign it might be a fraud, or you risk losing your money or getting a fake low-quality product.
When buying from Insulin.Store, we will kindly ask you to provide a valid prescription for the chosen drug. We will be able to proceed with your order just after successful verification of your prescription. In case it not valid or expired, our managers will ask you to upload a new document or cancel your order.
If you want to buy insulin for your pet, you will have to provide a prescription as well.
Insulin.Store, a Canadian pharmaceutical company, provides one of the best prices on the USA market for insulin and insulin-like products. Here are the prices for Fiasp on our website:
Please note that the prices may change. You can contact our sales managers or visit our website, Insulin.Store to check the current prices for all products presented in our online pharmacy.
Thousands of Americans are ordering Fiasp and other kinds of insulins from Canada. Why? Because Canadian companies provide much more beneficial prices than on the local USA market. And delivery is really fast – 4-10 business days. That is why many customers prefer buying their insulin supplies on Insulin.Store. How can you place an order with us?